(Q39356899)

11 September 2017

title

Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis (English)

1 reference

11 September 2017

0 references

Piyush Patel

1

1 reference

11 September 2017

George Philip

2

1 reference

11 September 2017

William Yang

3

1 reference

11 September 2017

Robert Call

4

1 reference

11 September 2017

Friedrich Horak

5

1 reference

11 September 2017

Craig LaForce

6

1 reference

11 September 2017

Leen Gilles

7

1 reference

11 September 2017

Graigory C Garrett

8

1 reference

11 September 2017

S Balachandra Dass

9

1 reference

11 September 2017

Barbara A Knorr

10

1 reference

11 September 2017

Theodore F Reiss

11

1 reference

11 September 2017

publication date

1 December 2005

1 reference

Annals of Allergy, Asthma & Immunology

11 September 2017

published in

1 reference

11 September 2017

volume

95

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

551-557

1 reference

Systemic immunologic and inflammatory aspects of allergic rhinitis

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

A review of montelukast in the treatment of asthma and allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

The effect of budesonide on the cytokine pattern in patients with perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

A 12-week, placebo-controlled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Intranasal capsaicin is lacking therapeutic effect in perennial allergic rhinitis to house dust mite. A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

Quality of life in adults and children with allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961018-6

7 January 2021

10.1016/S1081-1206(10)61018-6

Identifiers

DOI

1 reference

11 September 2017

1 reference